Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I
The DEA scheduling benzodiazepine analogs in Schedule I addresses the abuse potential of synthetic benzodiazepines. These substances pose significant clinical risks and regulatory challenges. Clinicians should be vigilant for exposure to these…
Temporary Scheduling of Bromazolam and Novel Benzodiazepines
The temporary scheduling of novel benzodiazepines such as bromazolam reflects regulatory efforts to address emerging abuse risks. This update highlights clinical toxicology concerns and enforcement under the Controlled Substances Act. Clinicians should…
DEA Update on Diphenidine Scheduling in Controlled Substances Act
The DEA scheduling diphenidine update reflects its placement in Schedule I due to high abuse potential and no accepted medical use. This regulatory action highlights challenges in controlling novel synthetic dissociatives. Clinicians should stay informed…
Federal Cannabis Rescheduling: Evidence-Based Policy Over Celebrity Opinion
The debate over federal cannabis rescheduling requires evidence-based policy decisions rather than celebrity-driven discourse. Current Schedule I classification restricts vital clinical research and creates legal barriers that complicate patient access…
FDA Cannabis Products Move from Schedule I to Schedule III Under New DEA Rule
The U.S. Department of Justice has proposed rescheduling FDA-approved cannabis-derived products from Schedule I to Schedule III, recognizing their medical utility while maintaining controlled substance oversight. This cannabis schedule III…
DEA Places Synthetic Cannabinoid CUMYL-PEGACLONE in Schedule I
The U.S. Drug Enforcement Administration has placed CUMYL-PEGACLONE, a synthetic cannabinoid analog, into Schedule I of the Controlled Substances Act due to its high abuse potential and lack of accepted medical use. This CUMYL-PEGACLONE Schedule I…
DEA Places 2-Fluorodeschloroketamine in Schedule I Controlled Substances
The DEA has temporarily placed 2-fluorodeschloroketamine in Schedule I of the Controlled Substances Act, reflecting regulatory action against emerging synthetic ketamine analogs. This DEA Schedule I classification demonstrates the federal approach to…
Policy Watch: DEA Schedule I Placement of Synthetic Cannabinoids — June 08, 2026
This Policy Watch covers DEA synthetic cannabinoids schedule I placement updates for June 08, 2026. These regulatory actions affect clinical and research practices involving controlled substances. Clinicians should stay informed about these changes to…
Cannabis policy priorities and public health- a survey of elected officials in California
This study reveals that among California elected officials, economic priorities dominate over health concerns. Despite cross-party consensus on youth packaging bans, implementation remains sparse.
Policy Watch: Key Synthetic Cannabinoids Schedule I Updates — June 02, 2026
This policy watch highlights synthetic cannabinoids Schedule I updates 2026 with significant clinical and regulatory implications. The DEA's recent actions classify several synthetic cannabinoids as Schedule I substances, affecting clinicians and…